Search Site

Neil A. Shneider, MD, PhD

  • Associate Professor of Neurology
  • Director, Eleanor and Lou Gehrig ALS Center
  • Director, ALSA/ALS Clinic
Neil A. Shneider, MD, PhD

Dr. Neil Shneider is a physician-scientist with expertise in neuromuscular development and disease. He is a graduate of Harvard College and of the MD-PhD program of the Columbia University College of Physicians and Surgeons, and he was Chief Resident of the Harvard Longwood Neurology Training Program.

Dr. Shneider completed his graduate work in the laboratory of Dr. Richard Axel and his postdoctoral fellowship in the laboratory of Dr. Thomas Jessell. After several years in the Intramural Program of the National Institute of Neurological Disorders and Stroke, Dr. Shneider returned to Columbia University as Assistant Professor of Neurology in the Neuromuscular Division. He is a member of the Center for Motor Neuron Biology and Disease and of the H. Houston Merritt Clinical Research Center. Dr. Shneider has clinical expertise in the diagnosis and care of patients with ALS and related motor neuron diseases. 

Models and Mechanisms of Motor Neuron Degeneration in Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease of the motor system that primarily involves spinal and bulbar motor neurons and their descending, corticospinal inputs.  ALS is genetically complex, and can be caused by mutations in a large and growing number of genes encoding proteins of diverse function.  Using mouse genetics, we have generated and characterized several animal and cellular models of ALS to explore molecular mechanisms of disease and to elucidate pathways of motor neuron degeneration that may be targets for drug discovery.  Work in the lab focuses on:

• the role of mutant FUS, TDP-43 and related ALS-associated RNA binding proteins in motor neuron degeneration.  In particular, we are interested in the propensity of these proteins to form abnormal ribonucleoprotein assemblies that are selectively toxic to motor neurons.  We use a combination of molecular, biochemical and computational methods to explore mechanisms of disease onset and progression in ALS

• molecular mechanisms of neurodegeneration caused by a hexanucleotide expansion in the gene C9orf72, the most common cause of familial ALS and frontotemporal dementia (FTD)

• the role of ALS mutant astrocytes and oligodendrocytes in the pathogenesis of ALS

• the role of motor neuron excitability and synaptic excitation in motor neuron dysfunction and degeneration

• genetic studies in novel animal and cellular models of ALS to validate promising pathways of disease; in vitro studies to screen small molecules and identify candidate therapeutics for ALS

In addition, our group is interested and involved in patient-based basic, translational and clinical research that focuses on:

• whole genome sequencing of ALS patients to elucidate novel disease pathways and potential targets

• phenotype-genotype correlation studies

• the generation and characterization of human, cellular models of ALS based on induced pluripotent stem cell (iPS) lines from clinically well-characterized patients

• early phase drug discovery

Departmental Appointments

  • Department of Neurology
    Division of Neuromuscular Medicine

Board Certifications

  • Neurology

Areas of Expertise

  • ALS (Amyotrophic Lateral Sclerosis)
  • Neuromuscular Disease
  • Lou Gehrig's Disease

Education & Training

  • BA, Harvard College
  • MD, Columbia College of Physicians and Surgeons
  • PhD, Columbia University, NY

Locations

  • Neurological Institute of New York

    710 West 168th Street
    Floor: 3
    New York, NY 10032
    For new and current patient appointments, call:
    (212) 305-1319

Centers/Institutes/Programs

  • ALS Center

Provider Affiliations

  • NewYork-Presbyterian/Columbia

Insurance Programs

Please contact the provider's office directly to verify that your particular insurance is accepted.

  • AARP [Medicare Managed Care]
  • Aetna [EPO, HMO, Medicare Managed Care, NY Signature, POS, PPO, Signature Administrators, Student Health]
  • Affinity [Access (Exchange), Essential Plan, Medicaid Managed Care, Medicare Managed Care]
  • Amida Care [Special Needs Plan]
  • Blue Shield [New Jersey]
  • Cigna [EPO, Great West, HMO, POS, PPO]
  • Emblem/GHI [HMO, Medicare Managed Care, PPO]
  • Emblem/HIP [ConnectiCare, EPO, Essential Plan, HMO, Medicaid Managed Care, Medicare Managed Care, POS, PPO, Select Care (Exchange), Vytra]
  • Empire Blue Cross Blue Shield [Blue Priority, EPO, HMO, Indemnity, Medicare (Mediblue), Medicare Managed Care, NYP Employee Plan, Pathway (Exchange), POS, PPO]
  • Empire Blue Cross Blue Shield HealthPlus [Child/Family Health Plus, Essential Plan, Medicaid Managed Care]
  • Fidelis Care [Child/Family Health Plus, Medicaid Managed Care, Medicare Managed Care]
  • Healthfirst [Child/Family Health Plus, Medicaid Managed Care, Medicare Managed Care]
  • Local 1199 [Local 1199]
  • MagnaCare [MagnaCare]
  • Medicare [Traditional Medicare (NY)]
  • Multiplan [Multiplan]
  • Oxford Health Plans [Freedom, Liberty, Medicare Managed Care]
  • POMCO [POMCO]
  • UnitedHealthcare [Columbia University Employee Plan, Compass (Exchange), EPO, Essential Plan, HMO, Medicaid (Community Plan), Medicare Managed Care, POS, PPO]
  • VNSNY CHOICE [SelectHealth]
  • WellCare [Medicaid Managed Care, Medicare Managed Care]

This provider accepts new patients

Appointment Phone Number: (212) 305-1319

Lab Locations

  • College of Physicians and Surgeons (P&S)

    630 West 168th Street
    P&S 5-432
    New York, NY 10032
    Fax:
    (212) 342-3109
    Lab Phone:
    (212) 342-3107
    Email:
    ns327@columbia.edu

Honors & Awards

2012 Stephen Q. Shafer Award for Humanism in Neurology

Research Interests

  • Neural Degeneration and Repair
  • Models of Neurological Disorders
  • Amyotrophic Lateral Sclerosis
  • Neurobiology of Disease
  • Genetic Basis of Neurological Disease

NIH Grants

  • SMN DYSFUNCTION IN FUS-DEPENDENT ALS (Federal Gov)

    Aug 15 2016 - Jul 31 2018

    THE ROLE OF PLD1 AND PLD2 IN NEURODEGENERATIVE PATHWAYS COMMON TO ALS AND AD (Private)

    Mar 7 2016 - Mar 6 2018

    GENE THERAPEUTIC MODULATION OF NMD FOR TEATMENT OF ALS (Private)

    Jan 1 2017 - Dec 31 2017

    EXPLORING THE MECHANISMS OF MUTANT FUS- MEDIATED MOTOR NEURON DEGENERATION IN ALS: AN IN VITRO APPROACH (Private)

    Dec 31 2016 - Dec 31 2017

    TARGET ALS POSTMORTEM CORE (Private)

    Jul 1 2016 - Jun 30 2017

    IDENTIFICATION OF LIPID BIOMARKERS FOR AMYOTROPHIC LATERAL SCLEROSIS (Private)

    Mar 15 2015 - Feb 14 2017

    ALSA PROPOSAL FOR ADDING BIOFLUIDS TO TARGET ALS POSTMORTEM TISSUE CORE (Private)

    Jan 1 2016 - Dec 31 2016

    EXPLORING THE MECHANISMS OF MUTANT FUS-MEDIATD MOTO NEURON DEGENERATION IN ALS: AN IN VITRO APPROACH APPROACH (Private)

    Dec 31 2015 - Dec 31 2016

    FUS/TLS GAIN AND LOSS OF FUNCTION IN ALS: ANIMAL AND CELLULAR MODELS OF DISEASE (Federal Gov)

    Sep 1 2011 - May 31 2016

    OPTINEURIN LOSS OF FUNCTION AS A MECHANISM OF MOTOR NEURON DEGENERATION IN ALS (Private)

    May 1 2014 - May 1 2016

    CELL AUTONOMOUS AND NON-CELL AUTONOMOUS MECHANISMS OF RNA-BINDING PROTEIN-MEDIATED MOTOR NEURON DEGENERATION IN ALS: AN IN VITRO APPROACH (Private)

    Dec 31 2013 - Dec 31 2015

    P2 ALS PHASE TWO: TESTING TARGETS (A COLLABORATIVE, GOAL-DRIVEN NETWORK FOR TRANSLATIONAL ALS RESEARCH) (Private)

    Feb 1 2013 - Dec 31 2015

    SHARED RESOURCES SUPPORT FOR SCI RESEARCH AT THE COLUMBIA MOTOR NEURON CENTER (NY State Gov)

    Dec 1 2014 - Aug 31 2015

    SHARED RESOURCES SUPPORT FOR SCI RESEARCH AT THE COLUMBIA MOTOR NEURON CENTER (NY State Gov)

    Oct 1 2014 - Feb 28 2015

    ALS GENOME SEQUENCING PROJECT (Private)

    Jun 18 2012 - Jun 17 2014

    P2 ALS INITIATIVE (Private)

    Jan 1 2010 - Dec 31 2013

    MOLECULAR PROFILING OF GAMMA MOTOR NEURON DEVELOPMENT (Federal Gov)

    Sep 1 2010 - Jun 30 2013